July 2026– date –
-
Akari Therapeutics and Whitehawk Therapeutics Partner on Trop2-Targeting ADC AKTX-101, Leveraging Novel PH1 Payload for Immune Activation
Markets Insider USA Overview Akari Therapeutics has entered a strategic research collaboration with Whitehawk Therapeutics to advance its next-generation Antibody-Drug Conjugate (ADC) lead candidate, AKTX-101. AKTX-101 targets the Trop2 ... -
bioRxiv Reports Novel AR Molecular Glue Degrader GZL626 Inhibits Prostate Cancer Cell Proliferation, Effective Against AR-V7
bioRxiv USA Overview A preprint published on bioRxiv reports a novel androgen receptor (AR) molecular glue degrader, GZL626. GZL626 was shown to induce proteasome-dependent degradation of both full-length AR and the AR splicing variant A... -
Optometrists Crucial for Ophthalmic Management of ADC Patients, Understanding Individualized Monitoring Requirements
Optometry Times USA Overview An Optometry Times article underscores the critical role of optometrists in the ophthalmic management of cancer patients undergoing Antibody-Drug Conjugate (ADC) therapy. Given that each ADC agent has unique ... -
FDA Approves First-in-Class PROTAC Degrader Vepdegestrant for ESR1-Mutated Breast Cancer, Improving Progression-Free Survival by 43%
Dana-Farber Cancer Institute USA Overview The U.S. FDA has approved vepdegestrant (Veppanu), a first-in-class PROTAC (Proteolysis-Targeting Chimera) degrader, for patients with ER-positive, HER2-negative metastatic breast cancer harborin... -
Nurix Therapeutics and Roche Secure HSR Clearance for Global Co-Development and Co-Commercialization Agreement of BTK Degrader Bexobrutideg
Nurix Therapeutics USA Overview Nurix Therapeutics announced HSR clearance for its global co-development and co-commercialization agreement with Roche for the BTK degrader bexobrutideg. Bexobrutideg is advancing in malignant hematology, ... -
Advances in Antibody-Drug Conjugate (ADC) Combination Therapy for Non-Small Cell Lung Cancer: Multi-Target Approaches with Trop-2, HER2, and More
PubMed USA Overview A PubMed review reports significant advances in Antibody-Drug Conjugate (ADC)-based combination therapy strategies for Non-Small Cell Lung Cancer (NSCLC). Focusing on diverse molecular targets such as Trop-2, HER2, HE... -
Arrowhead’s Plozasiran Achieves Up to 81% Triglyceride Reduction in Severe Hypertriglyceridemia Phase 3, Pressuring Ionis
Fierce Biotech USA Overview Arrowhead Pharmaceuticals has reported robust Phase 3 SHASTA-3 and SHASTA-4 trial data for its siRNA therapeutic, plozasiran, in patients with severe hypertriglyceridemia (sHTG), putting pressure on competitor... -
NIH Launches ‘TRDNT Challenge’ to Drive Development of Precision RNA-Targeting Therapeutics for Disease
NIH USA Overview The National Institutes of Health (NIH) has initiated Phase I of the 'Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge' to foster a new class of RNA-targeting technologies. This initiative aims to accel... -
Ribocure, a Suzhou Ribo Life Science Subsidiary, Reports 92% FXI Activity Reduction in Phase IIa Vortosiran Trial for Coronary Artery Disease
Clinical Trials Arena UK Overview Ribocure Pharmaceuticals, a subsidiary of Suzhou Ribo Life Science, announced promising initial results from its Phase IIa clinical trial of vortosiran (RBD4059), an siRNA therapy for coronary artery dis... -
Model-Optimized Bispecific Antibodies: A Novel Strategy to Enhance ADC Tumor Selectivity
Academia.edu USA Overview Research from Academia.edu elucidates the potential of computationally optimized bispecific antibodies (BsAbs) to enhance the tumor selectivity of Antibody-Drug Conjugates (ADCs). As ADC efficacy remains constra...
